title: Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease.
abstract: Genetic variation of matrix metalloproteinase 9 (MMP-9) gene polymorphism has been suggested to modulate coronary heart diseases (CHD), yet the underlying mechanisms are not well understood.
  
  
  
  We investigated the association of MMP9 rs3918242 single nucleotide polymorphism with inflammation and lipid-lowering efficacy after simvastatin treatment in Chinese patients with CHD. Fasting serum lipid profile and plasma inflammatory mediators were determined at baseline in 264 patients with CHD and 186 healthy control subjects, and after HMG-CoA reductase inhibitor simvastatin treatment (20 mg/day) for 12 weeks in CHD subjects.
  
  
  
  We found that plasma MMP-9, TNF-α and IL-10 levels were significantly elevated in patients with CHD compared to control subjects before treatment. The plasma MMP9 in CHD patients carrying rs3918242 CC, CT and TT genotypes were comparable. Interestingly, CHD patients carrying TT genotype had significantly higher level of triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) than those carrying CC genotype (P <0.05). Simvastatin treatment significantly reduced LDL-C, TG and plasma inflammatory mediator levels in CHD patients. The reduction of LDL-C upon simvastatin therapy was significantly greater in patients carrying TT genotype than those carrying CC genotype (P <0.05).
  
  
  
  MMP9 rs3918242 TT genotype is associated with elevated serum TG and LDL-C, and enhanced LDL-C-lowering response upon simvastatin treatment in Chinese patients with CHD.
  
  
  
  This study was retrospectively registered at Chinese Clinical Trial Registry (Registration number: ChiCTR-ROC-17010971 ) on March 23rd2017.
authors.affiliation: Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, 37 Yiyuan Rd, Nangang Region, Heilongjiang, Harbin, 150001, China.
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Xu
authors.affiliation: Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, 37 Yiyuan Rd, Nangang Region, Heilongjiang, Harbin, 150001, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, 37 Yiyuan Rd, Nangang Region, Heilongjiang, Harbin, 150001, China.
authors.forename: Jixin
authors.initials: J
authors.lastname: Zhi
authors.affiliation: Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, 37 Yiyuan Rd, Nangang Region, Heilongjiang, Harbin, 150001, China.
authors.forename: Lichun
authors.initials: L
authors.lastname: Qi
authors.affiliation: Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, 37 Yiyuan Rd, Nangang Region, Heilongjiang, Harbin, 150001, China.
authors.forename: Tong
authors.initials: T
authors.lastname: Zhang
authors.affiliation: Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, 37 Yiyuan Rd, Nangang Region, Heilongjiang, Harbin, 150001, China. Xueqili2016@outlook.com.
authors.forename: Xueqi
authors.initials: X
authors.lastname: Li
mesh_terms: D000368:Aged; D044466:Asian People / Q000235:genetics*; D008078:Cholesterol, LDL / Q000097:blood*; D003327:Coronary Disease / Q000188:drug therapy / Q000235:genetics*; D005260:Female; D014644:Genetic Variation / Q000235:genetics*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000235:genetics*; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D019821:Simvastatin / Q000627:therapeutic use*
chemical_list: D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019821:Simvastatin; C579270:MMP9 protein, human; D020780:Matrix Metalloproteinase 9
keywords: Coronary heart disease; Genetic polymorphism; HMG-CoA reductase inhibitor; MMP9